Assessing the BMD-Fracture Risk Relationship: A Meta-Regression Analysis
A meta-regression analysis indicated that greater improvements in BMD were strongly associated with greater reductions in fracture risk, especially in the vertebrae and hip.
Osteoporosis
Risk for Fragility Fractures Increased With Type 2 Diabetes
Type 2 diabetes is associated with significantly increased frailty and fracture risk compared with the general population.
Assessing Risk for Invasive Oral Events in Women Treated With Denosumab
Despite the relatively high prevalence of invasive oral events in women treated with denosumab, rates of osteonecrosis of the jaw remain low and tend to resolve with further therapy.
Vertebral Fracture Assessment Imaging May Predict Incident Fractures
Researchers examined the associations of prevalent vertebral fracture identified on vertebral fracture assessment images in routine practice with incident fractures.
Probiotics, Mucus Supplements Prevent Postantibiotic Bone Loss
Supplementation with probiotic Lactobacillus reuteri and mucus supplements significantly prevent bone loss from consequences of postantibiotic microbial gut dysbiosis.
BMD Improved Significantly With Denosumab vs Bisphosphonates in Osteoporosis
Results from a meta-analysis show that denosumab improved bone mineral density significantly more than bisphosphonates at the lumbar spine, total hip, and femoral neck.
Niacin Intake May Be Linked to Hip Fracture Risk in Older Adults
Both high and low niacin intake was associated with a risk for incident hip fractures in older adults.
Serum Estradiol Levels Predictive of Fractures During Menopausal Transition
Measuring serum estradiol during the menopausal transition might help identify women at higher risk for fractures.
Vitamin D, Calcium May Improve BMD in Postmenopausal Women With RA, Osteoporosis
Bone mineral density measures were significantly greater at 3 years in postmenopausal women with comorbid osteoporosis and rheumatoid arthritis who were given vitamin D and calcium supplementation.
FDA Panel Votes on Novel Osteoporosis Treatment Evenity
In the Biologics License Application (BLA) resubmission, Amgen and UCB proposed to narrow the indication to treatment of osteoporosis in postmenopausal women at high risk of fracture.
Next post in Bone Metabolism
